Skip to main content
Clinical Trials/NCT06223906
NCT06223906RecruitingNot Applicable

A Registry Study of Biomarkers in Heart Valve Disease

Beijing Institute of Heart, Lung and Blood Vessel Diseases1 site in 1 country200,000 target enrollmentStarted: January 1, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
200,000
Locations
1
Primary Endpoint
All-cause death

Study Overview

Brief Summary

Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the elderly and is on the rise. The primary conditions within this category are Aortic Stenosis and Mitral Regurgitation. These conditions are linked to considerable morbidity and mortality, presenting a formidable challenge in optimizing treatment strategies. Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study is to identify biomarkers involved in this disease using multi-omics approaches

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital

Exclusion Criteria

  • Age < 18 years
  • Failure to obtain medical records and ultrasound data
  • Refuse follow-up

Outcomes

Primary Outcomes

All-cause death

Time Frame: These data is collected during follow-up visit at 12 months after discharge

whether recidivation happened,whether other related disease happened

Secondary Outcomes

  • HF rehospitalization(These data is collected during follow-up visit at 12 months after discharge)

Investigators

Sponsor
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials